Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19738090 | 0.87 | CA12 (0.44) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL30594517 | 0.87 | CA12 (0.44) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL31456048 | 0.85 | MTNR1A (0.48) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL2497117 | 0.85 | L3MBTL1 (0.51) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL13303518 | 0.84 | TDP1 (0.48) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL5722672 | 0.84 | L3MBTL1 (0.46) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL15067190 | 0.82 | ALDH1A1 (0.59) | L3MBTL1MAPTHPGDNPC1RAB9A | |
| SCHEMBL2004375 | 0.82 | S1PR4 (0.51) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL17260308 | 0.81 | MAPT (0.50) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL15730490 | 0.81 | HTR7 (0.60) | L3MBTL1MAPTTDP1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| WO-2017218960-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2017-12-21 | — | — | WO | disclosed |
| WO-2010127208-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | L3MBTL1 1245/4885MAPT 476/4885TDP1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.